

# Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline Review, H1 2020

<https://marketpublishers.com/r/M9C80BB346CEN.html>

Date: May 2020

Pages: 487

Price: US\$ 2,000.00 (Single User License)

ID: M9C80BB346CEN

## Abstracts

Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline Review, H1 2020

### SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Pipeline Review, H1 2020.doc, provides an overview of the Methicillin-Resistant Staphylococcus aureus (MRSA) Infections (Infectious Disease) pipeline landscape.

MRSA infections that are acquired by persons who have not been recently (within the past year) hospitalized or had a medical procedure (such as dialysis, surgery, catheters) are known as community-acquired MRSA (CA-MRSA) infections. Risk factors are hemodialysis, weakened immune system, admission to hospitals and wounds. Symptoms include skin rashes, fatigue, chest pain, fever and swelling. MRSA can be managed by the use of antibiotics and by maintaining hygienic conditions.

### REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Pipeline Review, H1 2020.doc, provides comprehensive information on the therapeutics under development for Methicillin-Resistant Staphylococcus aureus (MRSA) Infections (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and

development history and latest news and press releases.

The Methicillin-Resistant Staphylococcus aureus (MRSA) Infections (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Methicillin-Resistant Staphylococcus aureus (MRSA) Infections and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 10, 14, 8, 2, 79, 31 and 1 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 32 and 26 molecules, respectively.

Methicillin-Resistant Staphylococcus aureus (MRSA) Infections (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

**Note:** Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

## SCOPE

The pipeline guide provides a snapshot of the global therapeutic landscape of Methicillin-Resistant Staphylococcus aureus (MRSA) Infections (Infectious Disease).

The pipeline guide reviews pipeline therapeutics for Methicillin-Resistant Staphylococcus aureus (MRSA) Infections (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products

which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Methicillin-Resistant Staphylococcus aureus (MRSA) Infections (Infectious Disease) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Methicillin-Resistant Staphylococcus aureus (MRSA) Infections (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Methicillin-Resistant Staphylococcus aureus (MRSA) Infections (Infectious Disease)

## **REASONS TO BUY**

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Methicillin-Resistant Staphylococcus aureus (MRSA) Infections (Infectious Disease).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Methicillin-Resistant Staphylococcus aureus (MRSA) Infections (Infectious Disease) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

## Contents

Introduction

Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Overview

Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Therapeutics

Development

Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Therapeutics

Assessment

Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Companies Involved in Therapeutics Development

Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Drug Profiles

Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Dormant Projects

Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Discontinued Products

Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Product Development

Milestones

Appendix

## List Of Tables

### LIST OF TABLES

Number of Products under Development for Methicillin-Resistant Staphylococcus aureus (MRSA) Infections, H1 2020

Number of Products under Development by Companies, H1 2020

Number of Products under Development by Companies, H1 2020 (Contd..1), H1 2020

Number of Products under Development by Companies, H1 2020 (Contd..2), H1 2020

Number of Products under Development by Companies, H1 2020 (Contd..3), H1 2020

Number of Products under Development by Companies, H1 2020 (Contd..4), H1 2020

Number of Products under Development by Companies, H1 2020 (Contd..5), H1 2020

Number of Products under Development by Companies, H1 2020 (Contd..6), H1 2020

Number of Products under Development by Universities/Institutes, H1 2020

Number of Products under Development by Universities/Institutes, H1 2020 (Contd..1), H1 2020

Number of Products under Development by Universities/Institutes, H1 2020 (Contd..2), H1 2020

Products under Development by Companies, H1 2020

Products under Development by Companies, H1 2020 (Contd..1), H1 2020

Products under Development by Companies, H1 2020 (Contd..2), H1 2020

Products under Development by Companies, H1 2020 (Contd..3), H1 2020

Products under Development by Companies, H1 2020 (Contd..4), H1 2020

Products under Development by Companies, H1 2020 (Contd..5), H1 2020

Products under Development by Companies, H1 2020 (Contd..6), H1 2020

Products under Development by Companies, H1 2020 (Contd..7), H1 2020

Products under Development by Universities/Institutes, H1 2020

Products under Development by Universities/Institutes, H1 2020 (Contd..1), H1 2020

Products under Development by Universities/Institutes, H1 2020 (Contd..2), H1 2020

Number of Products by Stage and Target, H1 2020

Number of Products by Stage and Target, H1 2020 (Contd..1), H1 2020

Number of Products by Stage and Target, H1 2020 (Contd..2), H1 2020

Number of Products by Stage and Mechanism of Action, H1 2020

Number of Products by Stage and Mechanism of Action, H1 2020 (Contd..1), H1 2020

Number of Products by Stage and Route of Administration, H1 2020

Number of Products by Stage and Molecule Type, H1 2020

Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by 21st Century Therapeutics Inc, H1 2020

Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Absynth

Biologics Ltd, H1 2020

Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by Acticule  
Life Sciences Ltd, H1 2020

Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by AEON  
Medix Inc, H1 2020

Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline by AimMax  
Therapeutics Inc, H1 2020

## List Of Figures

### LIST OF FIGURES

Number of Products under Development for Methicillin-Resistant Staphylococcus aureus (MRSA) Infections, H1 2020

Number of Products under Development by Companies, H1 2020

Number of Products under Development by Universities/Institutes, H1 2020

Number of Products by Top 10 Targets, H1 2020

Number of Products by Stage and Top 10 Targets, H1 2020

Number of Products by Top 10 Mechanism of Actions, H1 2020

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2020

Number of Products by Top 10 Routes of Administration, H1 2020

Number of Products by Stage and Top 10 Routes of Administration, H1 2020

Number of Products by Top 10 Molecule Types, H1 2020

Number of Products by Stage and Top 10 Molecule Types, H1 2020

### COMPANIES MENTIONED

21st Century Therapeutics Inc

Absynth Biologics Ltd

Acticule Life Sciences Ltd

AEON Medix Inc

AimMax Therapeutics Inc

Allergan Plc

AlphaMab Co Ltd

Amicrobe Inc

Amprologix Ltd

AnyGen Co Ltd

Aphios Corp

Aridis Pharmaceuticals Inc

Arietis Corp

Armata Pharmaceuticals Inc

Atriva Therapeutics GmbH

Aurigene Discovery Technologies Ltd

Basilea Pharmaceutica Ltd

Bharat Biotech Ltd

Biomendics LLC

BioPlx Microbiomics Pvt Ltd



Bioseka UAB  
Bioversys AG  
Botanix Pharmaceuticals Ltd  
Cadila Pharmaceuticals Ltd  
Cantab Anti-infectives Ltd  
Cellics Therapeutics Inc  
Citius Pharmaceuticals Inc  
Combioxin SA  
Crestone Inc  
CrystalGenomics Inc  
CSA Biotechnologies LLC  
Curza Global LLC  
Daiichi Sankyo Co Ltd  
Debiopharm International SA  
DeNovaMed Inc  
Destiny Pharma Plc  
Emerald Bioscience Inc  
ESA Patentverwertungsagentur Sachsen-Anhalt GmbH  
Exbaq LLC  
Galenus Therapeutics Inc  
GangaGen Inc  
Global BioLife Inc Ltd  
Helix BioMedix Inc  
Helperby Therapeutics Group Ltd  
Hsiri Therapeutics LLC  
HSRx Group  
HyPharm GmbH  
Idorsia Pharmaceutical Ltd  
Immupharma Plc  
Inimmune Corp  
Instituto Biomar SA  
Integrated BioTherapeutics Inc  
ioGenetics Inc  
Johnson & Johnson  
KBP BioSciences Co Ltd  
Kurobe LLC  
Lakewood-Amedex Inc  
Lead Discovery Center GmbH  
LegoChem Biosciences Inc

Lysimmune BioScience  
Lyticon LLC  
Madam Therapeutics BV  
Matrisys Bioscience Inc  
Meiji Seika Pharma Co Ltd  
Melinta Therapeutics Inc  
Merck & Co Inc  
MGB Biopharma Ltd  
Microbiotix Inc  
MicuRx Pharmaceuticals Inc  
Motif Bio Plc  
Nabriva Therapeutics Plc  
Naicons Srl  
Neupharma Srl  
Novabiotics Ltd  
NovaDigm Therapeutics Inc  
Novalex Therapeutics Inc  
NovoBiotic Pharmaceuticals LLC  
Olymvax Biopharmaceuticals Inc  
Opal Biosciences Ltd  
Oppilotech Ltd  
Oragenics Inc  
Oryn Therapeutics  
Ovensa Inc  
Oxford Drug Design Ltd  
Peptineo  
Phico Therapeutics Ltd  
Procarta Biosystems Ltd  
Pronmune Inc  
Q2 Pharma Ltd  
QureTech Bio AB  
Recce Pharmaceuticals Ltd  
Roivant Sciences Ltd  
Sano Chemicals Inc  
Savara Inc  
Scandion Oncology AS  
SciBac Inc  
Sealife PHARMA GMBH  
Sentinella Pharmaceuticals Inc

Shanghai Space Peptides Pharmaceutical Co Ltd  
Sinsa Labs Inc  
Soligenix Inc  
Sorrento Therapeutics Inc  
Synspira LLC  
TaeJoon Pharmaceuticals Co Ltd  
TAXIS Pharmaceuticals Inc  
Telephus Medical LLC  
TGV Laboratories Inc  
TGV-Inhalonix Inc  
Therapeutic Systems Research Laboratories Inc  
Theravance Biopharma Inc  
Trellis Bioscience Inc  
Valevia UK Ltd  
Venomyx Inc  
Viosera Therapeutics  
Vitas Pharma Research Pvt Ltd  
VLP Biotech Inc  
Wockhardt Ltd  
XBiotech Inc  
Yungjin Pharm Co Ltd  
Zhuhai Trinomab Biotechnology Co Ltd

## I would like to order

Product name: Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline Review, H1 2020

Product link: <https://marketpublishers.com/r/M9C80BB346CEN.html>

Price: US\$ 2,000.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/M9C80BB346CEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

